Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade.
Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade. NPJ Precis Oncol. 2024 Jan 02; 8(1):1.